Sage depression drug to get FDA panel review on Nov. 2

The FDA earlier today announced a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The committees will discuss the efficacy, safety, and benefit-risk profile of Sage Therapeutics’ new drug application for brexanolone for the proposed indication of postpartum depression on November 2.
https://thefly.com/landingPageNews.php?id=2795297